# Repligen share price today (Repligen Corporation, RGEN)

> Repligen Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. RGEN · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/rgen

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $178.27 (+19.6% in a year)
- P/E: 246.9× (higher than 65% of the last 4.6 years)
- Revenue (Jun 2026): $204 M (+11.9% on a year ago)
- Profit (Jun 2026): $5.0 M (−66.3% on a year ago)
- Operating margin: 9.3% (+4.8 points on a year ago)
- ROE: 2%, FY25
- ROIC: −4.8%, against a 9.3% cost of capital: −14.1 points

Biggest thing to watch: the P/E is higher than 65% of its own history, so the multiple has already done part of the work. ## What is the Repligen share price today? Repligen Corporation's share price was $178.27 at the close on 3 November 2026. It has been rising for 15 weeks. That is 23.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $103 and $190, and at that close it sat 87% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 22 weeks in a row. Over the last 10 years the share price moved +542% while the S&P 500 moved +255%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Repligen pay? Repligen Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Repligen on? Repligen is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Repligen profitable? Repligen Corporation earned $5.0 M of net profit in the Jun 2026 quarter, −66.3% on the same quarter a year earlier. Full-year FY25 profit was $48.9 M. Over 4 years profit has grown −21.4% a year on average. That is 2.5% of the quarter's revenue. The same quarter a year earlier earned $14.9 M. 3 of the last 12 reported quarters were loss-making. ## How much revenue does Repligen make, and is it growing? Repligen Corporation reported $204 M of revenue in the Jun 2026 quarter, +11.9% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 4 years it has grown 2.4% a year on average. The last full year, FY25, came in at $738 M. The last four reported quarters add to $785 M. FY25 revenue was $738 M, +16.4% on the year before. Recent pace: the last four quarters grew +16.7% on average, against 2.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.5%, against +12.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Repligen keep? Repligen Corporation's operating margin was 9.3% in the Jun 2026 quarter, 4.8 percentage points higher than the same quarter a year ago. Across 5 years it has been between 5.9% and 25.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +4.8 percentage points on the year while gross margin changed +2.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Repligen's profit turning into cash? Over the last 3 years, 149% of Repligen Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $117 M of operating cash against $48.9 M of profit. After $23.5 M of spending on assets, $93.9 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Repligen's cash go? Repligen Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $85.4 M on assets over the last 3 years. Averaged over those years that is 3.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $85.4 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Repligen's P/E ratio, and how does it compare with its own history? Repligen Corporation's P/E is 246.9×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 138.0×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +5.8% a year; about −25.7% a year came from earnings growth and about +31.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Repligen business getting better or worse? Repligen Corporation's business is getting worse. Profit and EPS growth are shrinking: profit growth is −245.8% in the latest quarter, against −39.4% at its best in 12 quarters, with ROCE steady at 2.3%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Repligen earn on its capital? Repligen Corporation earned a ROE of 2% in FY25. That is up from a low of −1% in FY24. Its return on capital used (ROIC) is 14.1 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 6.6% net margin and 0.25× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 6.6% net margin × 0.25× asset turnover × 1.40× leverage (assets divided by equity) ≈ 2.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −4.8% − 9.3% = −14.1 percentage points. The 9.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −4.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 1.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Repligen have too much debt? Repligen Corporation has total debt of $691 M against shareholder equity of $2.1 B as of Jun 2026, so its debt is 0.33× its equity. Year by year, that ratio went from 0.21 in FY21 to 0.33 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Repligen shareholding pattern? 11.7% of Repligen Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Repligen from balance-sheet trouble? For Repligen Corporation, the Z-score is 6.92. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.92 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Repligen rank in its industry? 50.5 out of 100, rank 10 of 30 in Medical Instruments & Supplies, with 74% of the evidence available. Repligen Corporation scores 50.5 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 22.6 + 8.9 + 3.7 + 15.3 = 50.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Repligen compared with? Repligen ranks 10 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 50.5 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. Repligen Corporation this page RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Repligen in size? Repligen is the 10th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Solventum Corporation, Baxter International Inc. and The Cooper Companies, Inc. Just below it: Align Technology, Inc., Avantor, Inc. and AptarGroup, Inc. ### Medical Instruments & Supplies companies close in size

1. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) $14.4 billion
2. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) $13.2 billion
3. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) $11.6 billion
4. Repligen Corporation $11.4 billion
5. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) $10.8 billion
6. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) $10.6 billion
7. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) $9 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [AGNC Investment Corp.](https://www.sectoralpha.in/us/stocks/agnc) $11.1 billion · REIT - Mortgage
2. [Graco Inc.](https://www.sectoralpha.in/us/stocks/ggg) $11.1 billion · Specialty Industrial Machinery
3. Repligen Corporation $11.1 billion
4. [Li Auto Inc.](https://www.sectoralpha.in/us/stocks/li) $11 billion · Auto Manufacturers
5. [SailPoint, Inc.](https://www.sectoralpha.in/us/stocks/sail) $11 billion · Software - Infrastructure

## What else do people ask about Repligen? ### What were Repligen's latest quarterly results? Repligen Corporation reported revenue of $204 M and net profit of $5.0 M for the Jun 2026 quarter. Revenue rose 11.9% and profit fell 66.3% compared with a year earlier. Earnings per share were $0.09. The operating margin was 9.3%, 4.8 percentage points higher than a year earlier (as of 3 November 2026). ### What is Repligen's market cap? Repligen Corporation's market capitalisation is $11.4 B at a stock price of $178.27. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Repligen performing? Repligen Corporation's share price has been rising for 15 weeks. In its latest quarter, revenue rose 11.9% and profit fell 66.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 22 weeks running (as of 3 November 2026). ### Will Repligen's stock price go up? This page does not forecast Repligen Corporation's stock price. What it shows instead: the stock price is $178.27, and it has been rising for 15 weeks. Its P/E of 246.9× is higher than 65% of its own last 5 years (as of 3 November 2026). ### Where is Repligen in its business cycle? Repligen Corporation's FY25 operating margin was 6.2%, against a 5-year range of 5.9% to 25.8%: the low end of its own range, which is often where recoveries start. The latest quarter was 9.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Repligen story? Biggest thing to watch: the P/E is higher than 65% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Repligen a stock worth studying right now? What the numbers show: Repligen Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.